RWS is going to have to wire the full USD 70m to CTi shareholders. In a short trading update related to the company’s Holdings Annual General Meeting on February 9, 2016, Chairman Andrew Brode disclosed that RWS expects CTi to deliver USD 33m in sales for the year ending December 31, 2015 (a big 43% jump from its 2014 revenue of USD 23m). Crucially, he also announced an unaudited EBITDA for CTi of not less than USD 8.5m for the same period.
As Slator had reported previously, the full USD 70m purchase price for the Connecticut-based life sciences translation and linguistic validation provider was contingent upon CTi reporting “not less than $7 million EBITDA for the year ended 31 December 2015.”
They achieved that, and then some. Brode also pointed out in the update that “the integration of CTi with the Group’s other life science activities is progressing well.”
